| Name | Title | Contact Details |
|---|
MEDX Ventures Group, founded in 2010, is an investment and management company with offices in Israel, USA and Europe. The company believes in active management (as opposed to passive investment), and is focusing on medical ventures and technologies in Israel while utilizing the Company`s unique X Model to include its core Development, Regulatory, Commercial and Finance team that manages a portfolio of ventures. MEDX Ventures Group capitalizes on its global presence while utilizing Israel`s unique research, development and operations capabilities in the field; As such the company focuses on smart investment, reduced risk, short time to market and efficient return on investment. MEDX Ventures Group is led by highly experienced medical device management and investment team from different aspects of the business to ensure the Company`s X Model is fully implemented and executed in each of its activities and ventures. In addition, the company continuously seeks alliances with global industry leaders, beginning in project development stage, to ensure medical innovations become the life changing reality for patients and providers, while becoming a profitable business to all stakeholders and generating attractive return for investors.
iData Research Inc. is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
InfraScan, Inc. is a medical device company that focuses on developing, commercializing, and distributing hand-held diagnostic devices for head injury and stroke assessment based on near infrared (NIR) technology. The Infrascanner enables clinicians to detect effectively, conveniently, and accurately intracranial bleeding in patients with head trauma. Intracranial hematomas are an important treatable cause of secondary brain injury in patients with head trauma. Recent statistics from Iraq shows that 30% of all wounded in action have head injuries; of them 40% have brain hematomas. Dr. Britton Chance (University of Pennsylvania) and Dr. Claudia Robertson (Baylor College of Medicine) invented a NIR system for detection of brain Hematomas and tested it successfully in 305 patients in Baylor. An entrepreneurial team formed a company around this technology in Collaboration with Drexel University and won the Wharton Business Plan competition in April 2004 and the second prize at the global business plan competition in Singapore in October 2004. Office of Naval Research funded the company in May 2004. The company also attracted $1.5M in funding from BioAdvance, the Biotechnology Greenhouse of Southeastern Pennsylvania, from Ben Franklin Technology Partners of Southeastern Pennsylvania, and from Philadelphia Industrial Development Corporation. A multicenter clinical study to support an FDA submission started in July 2006, and on February 2008 an application was submitted to the FDA. After 4 years of review, the FDA cleared Infrascanner Model 1000 as a DeNovo medical technology in December 2011. In January 2013 the FDA cleared the 510(k) of Infrascanner Model 2000.
Meridian Medical Technologies is a Columbia, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
With iCAD`s technology, cancer has finally met its match. As a global medical technology leader providing innovative cancer detection and therapy solutions, our technologies empower clinicians worldwide with an arsenal of tools to detect cancer and stop it in its tracks – streamlining workflow, improving accuracy, and personalizing results like never before. The ProFound AI Breast Health Suite is the first, best, and only complete, triple-threat solution that combines cancer detection, density assessment, and risk evaluation – all designed to accelerate discovery and improve outcomes. Our leading-edge cancer detection solution, ProFound AI®, is clinically proven to find cancers earlier and with greater accuracy, while slashing reading time for radiologists by more than half. PowerLook® Density Assessment simplifies and standardizes breast density reporting and stratification, offering consistent, accurate and reliable breast density categorization. And the latest addition to our Breast AI Suite, ProFound AI® Risk, is the world`s first clinical decision support tool that provides an accurate short-term breast cancer risk estimation that is truly personalized for each woman, based only on her mammogram. Our Xoft® Axxent® Electronic Brachytherapy (eBx®) System® is transforming the cancer treatment experience by empowering physicians to precisely and effectively target tumors anywhere in the body, anywhere in the world. Using the world`s smallest X-ray source, clinicians can precisely destroy disease while preserving healthy tissue, leaving cancer nowhere to hide.